Vapes

Search documents
Top Cannabis Stocks This Week: Market Trends, Chart Setups, and Risk Strategies
Marijuana Stocks | Cannabis Investments And News. Roots Of A Budding Industry.™· 2025-08-24 14:00
Industry Overview - The U.S. cannabis industry is rapidly expanding, with legal sales reaching nearly $30 billion in 2024 and projected to surpass $45 billion by 2028, driven by increased state legalization and changing consumer demand [1][3] - Federal rescheduling discussions are ongoing, with lawmakers considering moving cannabis to Schedule III, which could enhance banking access and reduce tax burdens [1][3] Key Companies - Green Thumb Industries Inc. (GTBIF), Curaleaf Holdings Inc. (CURLF), and Verano Holdings Corp. (VRNOF) are highlighted as top stocks to watch, each operating numerous dispensaries and possessing significant cultivation capacity [4][6][27] Green Thumb Industries Inc. (GTBIF) - Green Thumb operates over 90 dispensaries, primarily in Illinois, Pennsylvania, and Ohio, and is recognized as a vertically integrated operator with control over cultivation, processing, and retail [5][7] - The company reported quarterly revenue exceeding $275 million, maintaining profitability and showing resilience despite challenges in competitive markets [9][11] - Green Thumb's financials indicate improved margins due to higher retail sales and efficient operations, with stable debt levels enhancing financial flexibility [10][11] Curaleaf Holdings Inc. (CURLF) - Curaleaf operates over 140 dispensaries across more than 15 states, with a strong presence in Florida, New York, New Jersey, and Arizona [12][15] - The company posted quarterly revenue above $330 million, confirming its status as the largest revenue generator among U.S. cannabis companies, while also reducing operating losses [16][18] - Curaleaf's aggressive acquisition strategy and focus on high-demand markets position it as a competitive player in the industry [15][19] Verano Holdings Corp. (VRNOF) - Verano operates more than 140 dispensaries, primarily in Florida, New Jersey, and Illinois, and emphasizes customer experience and premium store design [19][21] - The company reported quarterly revenue of around $235 million, with positive adjusted EBITDA and improved operating income due to reduced expenses [24][25] - Verano's ongoing expansion and financial discipline, along with manageable debt levels, make it a significant competitor in the U.S. cannabis market [26][27]
Organigram (OGI) - 2025 Q3 - Earnings Call Presentation
2025-08-13 12:00
Financial Performance - Record gross revenue of $110.2 million, a 73% increase year-over-year and a 7.2% sequential increase[86] - Record net revenue of $70.8 million, a 72% increase year-over-year and a 7.9% sequential increase[86] - Adjusted EBITDA of $5.7 million, a 64% increase year-over-year and a 16% sequential increase[86] - International revenue reached $7.4 million, a 208% increase year-over-year and a 21% sequential increase[86] - Free cash flow was $5.0 million, compared to ($4.8) million in the prior year period[86] Strategic Initiatives - Completed the acquisition of Motif Labs Ltd, expecting approximately $15 million in run-rate cost synergies[44] - Completed the acquisition of Collective Project Limited, fast-tracking entry into the cannabinoid beverages category and the U S market[47] - Strategic investments from BAT totaled over $345 million to fund research & development and international M&A[48] - Invested $21 million into German cannabis leader Sanity Group to establish a foothold in the rapidly growing German market and expand export volume to Europe[61] - 27% of flower harvest at Moncton facility was seed-based in Q3 Fiscal 2025[65] Market Position - Organigram is the 1 LP in market share in Canada[17] - 1 in vapes, 1 in pre-rolls, 1 in milled flower, 1 in hash, 3 in edibles, 3 in dried flower in Canada[86]
British American Tobacco: Winds Of Change In The U.S. Market
Seeking Alpha· 2025-07-18 20:55
Core Viewpoint - British American Tobacco p.l.c. (NYSE: BTI) is recognized as the "second-best" tobacco company globally, with strong brand recognition and significant market shares, although it does not hold the top position like Marlboro [1]. Company Overview - British American Tobacco has a diverse portfolio that includes next-generation products such as heat-not-burn and vapes, indicating a strategic shift towards modern tobacco alternatives [1]. Market Position - The company maintains a competitive stance in the tobacco industry, leveraging its well-known brands to capture substantial market shares, although it is positioned behind Marlboro in terms of overall market leadership [1].
Why the Smartest Investors Are Buying Philip Morris International Stock and Not Altria
The Motley Fool· 2025-07-18 08:50
Core Insights - Altria has transitioned into a primarily tobacco-focused company, while Philip Morris International has a more diversified and stronger business model [1][4] Market Share and Brand Performance - Altria's flagship brand, Marlboro, holds a 41% market share in North America, contributing to an overall market share of approximately 45% when including smaller brands [3] - Marlboro has recently lost market share, indicating a decline in Altria's competitive position [5] Business Operations and Challenges - Altria's cigarette volume fell by 13.7% in Q1 2025, continuing a long-term downward trend, which is impacting its business significantly [5][6] - The company has faced substantial financial missteps, resulting in billions of dollars in write-downs, highlighting its struggles in adapting to market changes [6] Comparison with Philip Morris - Philip Morris has shown resilience, with cigarette volumes increasing in foreign markets during the same period, leading to a 0.4-percentage-point market share gain [7] - Philip Morris's non-cigarette operations are thriving, generating 42% of its revenue and 44% of its profits in Q1 2025, with strong performance in vapes and pouches [8] Investment Considerations - Investors in Altria are betting on the company's ability to pivot towards non-cigarette businesses, while Philip Morris is currently seen as the stronger investment option due to its successful execution and market performance [9]
Nicotine poisoning on the rise among children
NBC News· 2025-07-14 17:19
The number of young kids becoming sick after getting their hands on nicotine products like pouches and vapes, it has skyrocketed in recent recent years. According to a new study, US poison centers reported more than 130,000 cases of nicotine poisonings in kids under the age of six between 2010 and 2023. Now, that same study published by the American Academy of Pediatrics, it found an increase in poisonings of 763% in just 3 years.NBC News medical analyst Dr. . Vin Gupta joins us now. Dr.. Gupta, it's great ...
Buy Altria Stock? There Are 1.69 Billion Reasons to Worry.
The Motley Fool· 2025-06-06 08:10
Core Viewpoint - Altria Group, the largest cigarette maker in North America, is facing significant challenges due to declining cigarette volumes, despite rising earnings and dividends, raising concerns for investors [1][9]. Company Overview - Altria primarily focuses on cigarette production, with 14.2 billion cigarettes produced in Q1 2025, accounting for approximately 97% of its smokable products [3]. - Smokable products contribute around 88% to Altria's revenue, highlighting the importance of cigarettes to its business model [3]. Industry Trends - Cigarette volumes are declining, with a 13.7% decrease in production from nearly 16.5 billion in Q1 2024 to 14.2 billion in Q1 2025 [4]. - Historical data shows a significant drop from over 25 billion cigarettes produced in Q1 2020, indicating ongoing industry headwinds [4]. Company Strategies - Altria has attempted to mitigate the impact of declining cigarette demand through price increases, leveraging the addictive nature of nicotine to maintain some pricing power [5]. - However, recent trends suggest that price increases alone are insufficient to sustain revenue growth [6]. Financial Performance - Despite a year-over-year revenue decline of 5.7% in Q1 2025, generating approximately $5.3 billion compared to nearly $6.4 billion in 2020, Altria has managed to keep earnings and dividends rising [9]. - The company has reduced its share count from 1.758 billion in Q1 2024 to 1.69 billion in Q1 2025, primarily through stock buybacks, which has helped support earnings [7][10]. Future Outlook - While Altria currently offers a 6.7% dividend yield, the company must find alternatives to cigarettes to avoid a potential terminal decline [11].